Formulation of a Controlled-Release Carrier for 2-ketones Based on Solid Lipid Nanoparticles to Increase Seedling Growth in Lactuca sativa and Solanum lycopersicum

2021 ◽  
Author(s):  
Paola Fincheira ◽  
Olga Rubilar ◽  
Gonzalo Tortella ◽  
Cristian Medina ◽  
Amedea B Seabra ◽  
...  
Keyword(s):  
Controlled Release ◽  
Solanum Lycopersicum ◽  
Seedling Growth ◽  
Lactuca Sativa ◽  
Solid Lipid Nanoparticles ◽  
Lipid Nanoparticles ◽  
Solid Lipid

Chitosan-coated magnetic solid lipid nanoparticles for controlled release of letrozole

2020 ◽  
Vol 57 ◽  
pp. 101621 ◽  
Author(s):  
Zeynab Ahmadifard ◽  
Ahmad Ahmeda ◽  
Mahsa Rasekhian ◽  
Sajad Moradi ◽  
Elham Arkan
Keyword(s):  
Controlled Release ◽  
Solid Lipid Nanoparticles ◽  
Lipid Nanoparticles ◽  
Solid Lipid ◽  
Magnetic Solid

Solid lipid nanoparticle enhances bioavailability of hydroxycitric acid compared to a microparticle delivery system

RSC Advances ◽  
2016 ◽  
Vol 6 (59) ◽  
pp. 53784-53793 ◽  
Author(s):  
P. N. Ezhilarasi ◽  
S. P. Muthukumar ◽  
C. Anandharamakrishnan
Keyword(s):  
Controlled Release ◽  
Bioactive Compounds ◽  
Delivery System ◽  
Solid Lipid Nanoparticles ◽  
Lipid Nanoparticles ◽  
Solid Lipid Nanoparticle ◽  
Solid Lipid ◽  
Hydroxycitric Acid ◽  
System P ◽  
The Stability

Solid lipid nanoparticles (SLN) are the most promising delivery system that improves the stability, bioavailability and controlled release of food bioactive compounds.

Yak interferon-alpha loaded solid lipid nanoparticles for controlled release

2010 ◽  
Vol 88 (1) ◽  
pp. 148-153 ◽  
Author(s):  
Shaoyong Li ◽  
Baokai Zhao ◽  
Fenghua Wang ◽  
Ming Wang ◽  
Shuyu Xie ◽  
...  
Keyword(s):  
Controlled Release ◽  
Interferon Alpha ◽  
Solid Lipid Nanoparticles ◽  
Lipid Nanoparticles ◽  
Solid Lipid

scholarly journals Ciprofloxacin Controlled-Solid Lipid Nanoparticles: Characterization, In Vitro Release, and Antibacterial Activity Assessment

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Gamal A. Shazly
Keyword(s):  
Particle Size ◽  
Antibacterial Activity ◽  
Controlled Release ◽  
Solid Lipid Nanoparticles ◽  
In Vitro Release ◽  
Lipid Nanoparticles ◽  
Average Particle ◽  
Solid Lipid ◽  
Significant Difference

The objective of this research was to formulate ciprofloxacin (CIP) in solid lipid nanoparticles (SLNs) in an attempt to develop a controlled drug delivery system. An ultrasonic melt-emulsification method was used for preparing CIP-loaded SLNs. Key findings included that SLNs were successfully produced with average particle sizes ranging from 165 to 320 nm and polydispersity index in the range of 0.18–0.33. High entrapment efficiency values were reported in all formulations. The atomic force scanning microscopic images showed spherical shape with the size range closer to those found by the particle size analyzer. CIP release exhibited controlled-release behavior with various lipids. Ciprofloxacin solid lipid nanoparticles formula containing stearic acid (CIPSTE) displayed the strongest burst effect and the most rapid release rate. The release data revealed a better fit to the Higuchi diffusion model. After storing the CIPSTE formula at room temperature for 120 days, no significant difference in particle size and zeta potential was found. CIP-loaded SLNs exhibited superior antibacterial activity. Incorporation of CIP into SLNs leads to controlled release and a superior antibacterial effect of CIP.

scholarly journals Preparation of Co-Processed Excipients for Controlled-Release of Drugs Assembled with Solid Lipid Nanoparticles and Direct Compression Materials

Molecules ◽  
2021 ◽  
Vol 26 (7) ◽  
pp. 2093
Author(s):  
Luis Eduardo Serrano-Mora ◽  
María L. Zambrano-Zaragoza ◽  
Néstor Mendoza-Muñoz ◽  
Gerardo Leyva-Gómez ◽  
Zaida Urbán-Morlán ◽  
...  
Keyword(s):  
Controlled Release ◽  
Solid Lipid Nanoparticles ◽  
Control Release ◽  
Lipid Nanoparticles ◽  
Fickian Diffusion ◽  
Direct Compression ◽  
Class Iii ◽  
Solid Lipid ◽  
Powder Rheology ◽  
Good Flow

The purpose of the study was to develop a novel, directly compressible, co-processed excipient capable of providing a controlled-release drug system for the pharmaceutical industry. A co-processed powder was formed by adsorption of solid lipid nanoparticles (SLN) as a controlled-release film onto a functional excipient, in this case, dicalcium phosphate dihydrate (DPD), for direct compression (Di-Tab®). The co-processed excipient has advantages: easy to implement; solvent-free; industrial scaling-up; good rheological and compressibility properties; and the capability to form an inert platform. Six different batches of Di-Tab®:SLN weight ratios were prepared (4:0.6, 3:0.6, 2:0.6, 1:0.6, 0.5:0.6, and 0.25:0.6). BCS class III ranitidine hydrochloride was selected as a drug model to evaluate the mixture’s controlled-release capabilities. The co-processed excipients were characterized in terms of powder rheology and dissolution rate. The best Di-Tab®:SLN ratio proved to be 2:0.6, as it showed high functionality with good flow and compressibility properties (Carr Index = 16 ± 1, Hausner Index = 1.19 ± 0.04). This ratio could control release for up to 8 h, so it fits the ideal profile calculated based on biopharmaceutical data. The compressed systems obtained using this powder mixture behave as a matrix platform in which Fickian diffusion governs the release. The Higuchi model can explain their behavior.

Sign in / Sign up

Export Citation Format

Share Document